Scinai Immunotherapeutics Ltd. announced the completion of its acquisition of 100% of the shares of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions expand Scinai’s CDMO manufacturing footprint and capabilities, enabling end-to-end development and manufacturing services.
Key takeaways
Scinai acquired 100% of Recipharm Israel Ltd. shares via Share Purchase Agreement.
Recipharm Israel Ltd. operates cGMP site in Yavne, Israel, for early chemistry development and small-scale API manufacturing.
Acquisition structured as share purchase to preserve operational continuity, including employees, quality systems, and customer contracts.
Entered Commercial Collaboration Agreement with Recipharm for mutual preferred partner status across development lifecycle.
Collaboration includes Master Quality Agreement and Tech Transfer Framework Agreement.
Expanded capabilities cover recombinant proteins, small molecules, peptides, antibodies, and oligonucleotides.